The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
Abstract
Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Wild-type p53 interacts with its negative regulators, which mainly include MDM2/4 (Fig. 1c-f), to maintain its low expression.190,191”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Self-citationSchafmeister, C. E., Po, J., & Verdine, G. L. (2000) · Journal of the American Chemical Society · doi:10.1021/ja000563a · Cited by 1,037
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Direct inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
Self-citationStructure of the Stapled p53 Peptide Bound to Mdm2
Baek, S., Kutchukian, P. S., Verdine, G. L., Huber, R., Holak, T. A., Lee, K. W., & Popowicz, G. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2090367 · Cited by 259
Marine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Self-citationTargeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
Self-citation
Research works printed but not linked: 53
- Lane, 1992, Cancer. P53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
- Vogelstein, 2000, Surfing the P53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
- Vousden, 2007, P53 in health and disease, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
- Haupt, 1997, MDM2 promotes the rapid degradation of P53, Nature, 387, 296, 10.1038/387296a0 · DOI · Paper page
- Xue, 2007, Senescence and tumour clearance is triggered by P53 restoration in murine liver carcinomas, Nature, 445, 656, 10.1038/nature05529 · DOI · Paper page
- Khoo, 2014, Drugging the P53 pathway: understanding the route to clinical efficacy, Nat Rev Drug Discov, 13, 217, 10.1038/nrd4236 · DOI · Paper page
- Zhang, 2014, Targeting P53‒MDM2‒MDMX loop for cancer therapy, Subcell Biochem, 85, 281, 10.1007/978-94-017-9211-0_16 · DOI
- Momand, 1992, The mdm-2 oncogene product forms a complex with the P53 protein and inhibits P53-mediated transactivation, Cell, 69, 1237, 10.1016/0092-8674(92)90644-R · DOI · Paper page
- Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor P53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
- Zhan, 2011, Peptide activators of the P53 tumor suppressor, Curr Pharm Des, 17, 603, 10.2174/138161211795222577 · DOI
- Fasan, 2004, Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the P53‒HDM2 protein‒protein interaction, Angew Chem Int Ed Engl, 43, 2109, 10.1002/anie.200353242 · DOI · Paper page
- Harker, 2009, Beta-peptides with improved affinity for hDM2 and hDMX, Bioorg Med Chem, 17, 2038, 10.1016/j.bmc.2009.01.039 · DOI
- Li, 2009, Apamin as a template for structure-based rational design of potent peptide activators of P53, Angew Chem Int Ed Engl, 48, 8712, 10.1002/anie.200904550 · DOI
- Kritzer, 2006, Miniature protein inhibitors of the P53‒hDM2 interaction, Chembiochem, 7, 29, 10.1002/cbic.200500324 · DOI
- Hu, 2007, Efficient P53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX, Cancer Res, 67, 8810, 10.1158/0008-5472.CAN-07-1140 · DOI · Paper page
- Li, 2008, Turning a scorpion toxin into an antitumor miniprotein, J Am Chem Soc, 130, 13546, 10.1021/ja8042036 · DOI
- Vassilev, 2004, In vivo activation of the P53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
- Li, 2010, Systematic mutational analysis of peptide inhibition of the P53-MDM2/MDMX interactions, J Mol Biol, 398, 200, 10.1016/j.jmb.2010.03.005 · DOI
- Schnolzer, 1992, In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences, Int J Pept Protein Res, 40, 180, 10.1111/j.1399-3011.1992.tb00291.x · DOI · Paper page
- Dawson, 2000, Synthesis of native proteins by chemical ligation, Annu Rev Biochem, 69, 923, 10.1146/annurev.biochem.69.1.923 · DOI · Paper page
- Dawson, 1994, Synthesis of proteins by native chemical ligation, Science, 266, 776, 10.1126/science.7973629 · DOI · Paper page
- Pace, 1995, How to measure and predict the molar absorption coefficient of a protein, Protein Sci, 4, 2411, 10.1002/pro.5560041120 · DOI · Paper page
- Li, 2010, Limitations of peptide retro-inverso isomerization in molecular mimicry, J Biol Chem, 285, 19572, 10.1074/jbc.M110.116814 · DOI
- Zhan, 2012, Interrogation of MDM2 phosphorylation in P53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined, J Am Chem Soc, 134, 6855, 10.1021/ja301255n · DOI
- Zhan, 2012, An ultrahigh affinity d-peptide antagonist of MDM2, J Med Chem, 55, 6237, 10.1021/jm3005465 · DOI
- Otwinowski, 1997, Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol, 276, 307, 10.1016/S0076-6879(97)76066-X · DOI · Paper page
- Murshudov, 1997, Refinement of macromolecular structures by the maximum-likelihood method, Acta Crystallogr D Biol Crystallogr, 53, 240, 10.1107/S0907444996012255 · DOI · Paper page
- Li, 2019, Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design, Chem Sci, 10, 1522, 10.1039/C8SC03275K · DOI
- Dill, 1997, Additivity principles in biochemistry, J Biol Chem, 272, 701, 10.1074/jbc.272.2.701 · DOI · Paper page
- Wells, 1990, Additivity of mutational effects in proteins, Biochemistry, 29, 8509, 10.1021/bi00489a001 · DOI · Paper page
- Li, 2020, Stapled helical peptides bearing different anchoring residues, Chem Rev, 120, 10079, 10.1021/acs.chemrev.0c00532 · DOI · Paper page
- Brown, 2013, Stapled peptides with improved potency and specificity that activate P53, ACS Chem Biol, 8, 506, 10.1021/cb3005148 · DOI · Paper page
- Chen, 2015, A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through P53 activation, J Control Release, 218, 29, 10.1016/j.jconrel.2015.09.061 · DOI
- Zhao, 2014, Mirror image proteins, Curr Opin Chem Biol, 22, 56, 10.1016/j.cbpa.2014.09.019 · DOI
- Craik, 2013, The future of peptide-based drugs, Chem Biol Drug Des, 81, 136, 10.1111/cbdd.12055 · DOI · Paper page
- Bernal, 2007, Reactivation of the P53 tumor suppressor pathway by a stapled P53 peptide, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page
- Bautista, 2010, Bridged beta(3)-peptide inhibitors of P53‒hDM2 complexation: correlation between affinity and cell permeability, J Am Chem Soc, 132, 2904, 10.1021/ja910715u · DOI
- Zhang, 2011, Antiviral activity of alpha-helical stapled peptides designed from the HIV-1 capsid dimerization domain, Retrovirology, 8, 28, 10.1186/1742-4690-8-28 · DOI
- Takada, 2012, Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling, Sci Transl Med, 4, 148ra117, 10.1126/scitranslmed.3003808 · DOI · Paper page
- Phillips, 2011, Design and structure of stapled peptides binding to estrogen receptors, J Am Chem Soc, 133, 9696, 10.1021/ja202946k · DOI · Paper page
- LaBelle, 2012, A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers, J Clin Invest, 122, 2018, 10.1172/JCI46231 · DOI · Paper page
- Grossmann, 2012, Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin, Proc Natl Acad Sci U S A, 109, 17942, 10.1073/pnas.1208396109 · DOI · Paper page
- Bernal, 2011, A stapled P53 helix overcomes HDMX-mediated suppression of P53, Cancer Cell, 18, 411, 10.1016/j.ccr.2010.10.024 · DOI · Paper page
- Brown, 2013, Stapled peptides with improved potency and specificity that activate P53, ACS Chem Biol, 15, 506, 10.1021/cb3005148 · DOI · Paper page
- Chang, 2013, Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for P53-dependent cancer therapy, Proc Natl Acad Sci U S A, 110, E3445, 10.1073/pnas.1303002110 · DOI · Paper page
- Philippe, 2016, Development of cell-penetrating peptide-based drug leads to inhibit MDMX: P53 and MDM2: P53 interactions, Biopolymers, 106, 853, 10.1002/bip.22893 · DOI
- Eckert, 1999, Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket, Cell, 99, 103, 10.1016/S0092-8674(00)80066-5 · DOI · Paper page
- Schumacher, 1996, Identification of d-peptide ligands through mirror-image phage display, Science, 271, 1854, 10.1126/science.271.5257.1854 · DOI · Paper page
- Liu, 2010, d-peptide inhibitors of the P53–MDM2 interaction for targeted molecular therapy of malignant neoplasms, Proc Natl Acad Sci U S A, 107, 14321, 10.1073/pnas.1008930107 · DOI · Paper page
- Zhan, 2015, Toxins and derivatives in molecular pharmaceutics: drug delivery and targeted therapy, Adv Drug Deliv Rev, 90, 101, 10.1016/j.addr.2015.04.025 · DOI
- Yan, 2021, A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity, Theranostics, 11, 6833, 10.7150/thno.59020 · DOI
- He, 2019, Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy, Adv Funct Mater, 29, 1807736, 10.1002/adfm.201807736 · DOI
- Brunger, 1997, Free R value: cross-validation in crystallography, Methods Enzymol, 277, 366, 10.1016/S0076-6879(97)77021-6 · DOI · Paper page
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., & Lu, W.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 11
- Issue
- 9
- Pages
- 2655-2669
- ISSN
- 2211-3835
- Cited by
- 42
- References
- 24
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institutes of Health
- National Natural Science Foundation of China (21807112, 22077078, 82030062, 91849129)
- U.S. Department of Energy
- Shanghai Rising-Star Program
- National Institute of General Medical Sciences
- Office of Science
- Biological and Environmental Research
- Basic Energy Sciences (DE-AC02-76SF00515)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.